310 related articles for article (PubMed ID: 25496333)
1. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Smyth EC; Tarazona N; Chau I
Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
3. Ramucirumab: a novel antiangiogenic agent.
Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
[TBL] [Abstract][Full Text] [Related]
4. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
Ueda S; Satoh T; Gotoh M; Gao L; Doi T
Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Ramucirumab for Gastric Cancer.
Casak SJ; Fashoyin-Aje I; Lemery SJ; Zhang L; Jin R; Li H; Zhao L; Zhao H; Zhang H; Chen H; He K; Dougherty M; Novak R; Kennett S; Khasar S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Aug; 21(15):3372-6. PubMed ID: 26048277
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
7. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
Javle M; Smyth EC; Chau I
Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.
Tabernero J; Ohtsu A; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Ajani JA; Tomasek J; Safran H; Chandrawansa K; Hsu Y; Heathman M; Khan A; Ni L; Melemed AS; Gao L; Ferry D; Fuchs CS
Mol Cancer Ther; 2017 Oct; 16(10):2215-2222. PubMed ID: 28716815
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic agent ramucirumab: meaningful or marginal?
Wadhwa R; Elimova E; Shiozaki H; Sudo K; Blum MA; Estrella JS; Chen Q; Song S; Ajani JA
Expert Rev Anticancer Ther; 2014 Apr; 14(4):367-79. PubMed ID: 24605771
[TBL] [Abstract][Full Text] [Related]
13. Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.
van der Woude SO; van Laarhoven HW
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539134
[TBL] [Abstract][Full Text] [Related]
14. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
[TBL] [Abstract][Full Text] [Related]
16. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Satake H; Sagawa T; Fujikawa K; Hatachi Y; Yasui H; Kotaka M; Kato T; Tsuji A
Cancer Chemother Pharmacol; 2018 Nov; 82(5):839-845. PubMed ID: 30167847
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.
Hofheinz RD; Lorenzen S
Expert Rev Anticancer Ther; 2015 Jun; 15(6):607-14. PubMed ID: 26035718
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Khan U; Shah MA
Expert Opin Biol Ther; 2019 Nov; 19(11):1135-1141. PubMed ID: 31452409
[No Abstract] [Full Text] [Related]
19. Ramucirumab: first global approval.
Poole RM; Vaidya A
Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
Krupitskaya Y; Wakelee HA
Curr Opin Investig Drugs; 2009 Jun; 10(6):597-605. PubMed ID: 19513949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]